Marion Jones arrived at the Sydney 2000 Olympics promising to win five track-and-field medals and left having won exactly that — three gold (100m, 200m, 4x400m relay) and two bronze (long jump, 4x100m relay) — the most decorated American woman of the Games and, for the better part of a decade, one of the most celebrated athletes in the world. On December 12, 2007, the International Olympic Committee disqualified her from all five events and stripped every medal. The verdict on the haul was: stripped.
The substance at the centre of it was “the clear,” a designer steroid known as THG, supplied through the Bay Area Laboratory Co-operative — BALCO — that for years sat undetectable because no test had been designed to look for it. Jones’s coach, Trevor Graham, gave it to her; she would later say he told her it was flaxseed oil, a claim that is either the truth or the most convenient version of it, and which in the end mattered to no authority that ruled on her case.
What destroyed Marion Jones was not, in the strict sense, the doping. It was the lying about it. For years she denied any use of performance-enhancing drugs, sued an accuser, and built a public defence on indignant denial. When federal investigators questioned her in connection with the BALCO inquiry — and a separate check-fraud scheme — she lied to them, and lying to federal agents is itself a crime. On October 5, 2007, she pleaded guilty in a New York federal court to two counts of making false statements. On January 11, 2008, she was sentenced to six months in prison. The medals were a sporting matter; the cell was a criminal one.
The case is the clearest illustration in the doping canon of a particular lesson: that the cover-up is reliably more dangerous than the conduct it conceals. The doping cost Jones her medals, records, sponsors, and reputation — serious, but survivable. The denial, sustained to federal agents, cost her freedom. The record now reads that the woman who won five medals in Sydney won none of them, and went to prison for insisting otherwise.
The Bay Area Laboratory Co-Operative — BALCO — presented itself as a humble nutritional supplement company in Burlingame, California, run by a former funk bassist named Victor Conte. What it actually ran, for several years up to 2003, was a doping operation built around a steroid that no drug test could find. On February 12, 2004, a federal grand jury returned a 42-count indictment against Conte and three associates for conspiracy, distribution of anabolic steroids, and money laundering. On July 15, 2005, Conte pleaded guilty to one count of conspiracy to distribute steroids and one count of money laundering. In October 2005 he was sentenced to four months in federal prison and four months of house arrest. The verdict on record is a criminal conviction.
The edge BALCO sold was chemistry the testers had never seen. Its signature product, tetrahydrogestrinone — “the clear” — was a synthetic anabolic steroid deliberately engineered to be invisible to the standard urine assays of the day. Alongside it came “the cream,” a testosterone-and-epitestosterone ointment designed to mask the hormonal ratios doping tests measured, plus human growth hormone, EPO, and modafinil. The drugs reached more than 30 elite athletes across track and field, Major League Baseball, and the NFL — among them sprinters Marion Jones and Tim Montgomery and baseball’s Barry Bonds and Jason Giambi.
The scheme that no laboratory could detect was undone by the lowest-tech intervention imaginable: in June 2003 an anonymous coach mailed a used syringe of “the clear” to the US Anti-Doping Agency. A chemist reverse-engineered it, built a test, and screened hundreds of stored samples. Suddenly the undetectable was detectable, and the athletes who had banked on permanent invisibility were standing in the open.
What followed was a cascade. Conte and his co-defendants took plea deals and short sentences. The athletes took bans — most for two to four years — and in the highest-profile case, Marion Jones surrendered five Olympic medals and went to federal prison, not for doping but for lying to investigators about it. The lab that promised its clients they would never be caught had, in the end, caught all of them.
Between the early 1970s and German reunification in 1990, the German Democratic Republic ran the most comprehensive state-organized doping program in the history of sport. It was not the work of rogue coaches or individual cheats. It was government policy, codified in 1974 as a state research plan and administered through the country’s sports and medical hierarchy. On July 18, 2000, a Berlin court convicted the former head of the GDR sports federation, Manfred Ewald, and the program’s chief medical overseer, Dr. Manfred Höppner, as accessories to the intentional bodily harm of athletes, including minors. Ewald received a 22-month suspended sentence; Höppner received an 18-month suspended sentence. Those convictions are the verdict on record.
The program’s principal drug was Oral-Turinabol, an anabolic steroid manufactured by the state-owned pharmaceutical firm Jenapharm. It was given to athletes across many sports, frequently to teenage girls, and frequently without their knowledge or informed consent. Many were told they were taking vitamins. The doses were calibrated by sport and tracked centrally, and the medical apparatus that administered the steroids was the same apparatus that worked to keep athletes from testing positive in international competition. Estimates of the number of athletes affected run to roughly 10,000 over the program’s lifetime.
The harm was real and, for many, permanent. Female athletes experienced virilization; athletes of both sexes have suffered cardiovascular disease, liver and reproductive damage, and serious psychological consequences. The most widely known case is that of Heidi Krieger, the 1986 European shot put champion, who was doped from her teens and who has said the steroids contributed to a gender identity she was never given the chance to discover for herself; she underwent gender-reassignment surgery in 1997 and lives as Andreas Krieger. The damage done to the people the state was meant to represent is the center of this case.
The trials that followed reunification could not undo any of that. They established, as a matter of law, that officials at the top of the system had knowingly caused bodily harm to athletes in their care, and that some of those athletes were children who could not have consented even if they had been asked.
Rashid Ramzi, the Moroccan-born middle-distance runner who competed for Bahrain, won the 1500 metres at the 2008 Beijing Olympics and, on November 18, 2009 — some fifteen months later — was stripped of the gold by the International Olympic Committee for doping with CERA, a third-generation form of EPO. He had passed his doping controls at the Games. The samples were not flawed; the test had simply not yet been good enough to read them, and when it improved, the IOC went back and read them again. Kenya’s Asbel Kiprop was promoted to gold, New Zealand’s Nicholas Willis to silver, and France’s Mehdi Baala to bronze. Ramzi was the only champion of the Beijing Games caught in the re-analysis.
The substance was the case’s signature. CERA — continuous erythropoietin receptor activator, sold by Roche as Mircera under the generic name methoxy polyethylene glycol-epoetin beta — is an engineered descendant of recombinant EPO designed to last far longer in the body, with the longest half-life of any approved erythropoiesis-stimulating agent. That endurance is the point for a kidney patient, who can be dosed once or twice a month instead of several times a week. It is also, for an athlete trying to evade detection, a serious miscalculation: a molecule built to linger is a molecule that lingers in a stored sample, waiting to be found. CERA had been approved in Europe in August 2007 and by the US FDA in January 2008, and within months it was turning up at the 2008 Tour de France. By Beijing, the laboratories were closing the gap.
The mechanism that undid Ramzi was not a tip-off or a confession but the IOC’s policy of freezing Olympic samples and re-testing them when the science advances. The Beijing samples were collected in August 2008 and cleared at the time. In 2009, once a fully validated CERA assay existed, the IOC thawed a batch and ran it again. Five athletes failed the second look; Ramzi’s was the only gold among them. His B-sample was confirmed positive in July 2009, and the IOC ratified the disqualification that November.
What followed was comparatively quiet. Ramzi, who had been the first Bahraini to win an Olympic athletics title and one of the few men ever to take the 800m–1500m double at a World Championships, lost the medal and served a two-year ban. There was no career rehabilitation to forgive, because there was barely a career left. The case endures less for its drama than for what it proved about time: that the finish line is not the end of the contest, and that a clean result in 2008 was only ever provisional.
Justin Gatlin, the American sprinter who won the Olympic 100m in Athens in 2004, was banned from athletics in 2006 after testing positive for testosterone, a sanction that annulled the 9.77-second world record he had set weeks earlier and, because it counted as his second doping offence, very nearly ended his career for good. The United States Anti-Doping Agency initially announced an eight-year ban — a near-lifetime penalty for a sprinter then 24 — which an arbitration panel reduced to four years in December 2007. Gatlin returned to competition in August 2010, and then did the thing the sport could not metabolize: he won. Olympic bronze in 2012, Olympic silver in 2016, and a world title in 2017 in which he beat Usain Bolt in Bolt’s final individual race. The medals were legitimate. The booing that greeted them was a verdict the rule book could not impose.
The 2006 case was, on its face, simple. An in-competition test at the Kansas Relays on April 22, 2006 returned positive for testosterone or its precursors. The B-sample confirmed it that July. The complication was history. Five years earlier, as a freshman at the University of Tennessee, Gatlin had tested positive for an amphetamine at the 2001 US junior championships — a finding traced to Adderall he had taken since childhood for attention-deficit disorder. An arbitration panel at the time called him “certainly not a doper” and the violation “at most, a technical or a paperwork” matter, and the IAAF granted early reinstatement on the strength of the medical explanation. It was, by any reasonable reading, the least sinister positive test imaginable. Under the rules, it was still a first offence.
That technicality governed everything that followed. A first amphetamine positive plus a testosterone positive is, in anti-doping arithmetic, a repeat offender, and the testosterone case therefore carried the weight of a second strike regardless of how innocuous the first had been. Gatlin’s camp blamed a massage therapist for rubbing a testosterone cream onto him without his knowledge — an explanation never substantiated — but the substance, the test, and the prior record were not in dispute. The eight-year ban reflected the recidivism; the reduction to four reflected his cooperation and the genuine ambiguity of the 2001 case.
What the verdict could not settle was the matter of forgiveness. Gatlin served his time, came back, and ran faster in his thirties than most men do in their twenties, which left the sport in an awkward position: he had paid the penalty the system prescribed and was therefore entitled to compete, yet he was treated as the ban had never lifted. The crowds booed an athlete who was, by the rules’ own logic, rehabilitated. His career became the test case for a question the sport has never resolved — whether a served sentence is a clean slate, or merely permission to be hated in public.